Regeneron's COVID-19 Cocktail Helps Prevent Symptomatic Disease
https://www.newsmax.com/newsfront/regeneron-coronavirus-symptom-prevention/2021/04/12/id/1017217/12 April 2021
...REGEN-COV, as the combination shot of casirivimab and imdevimab is called, reduced the overall risk of progressing to symptomatic COVID-19 by 31%, and by 76% after the third day. The trial also demonstrated that it shortened symptom duration and markedly lowered viral levels, Regeneron said in a statement....
...The drug has emergency U.S. approval for mild to moderate COVID-19 patients, and the companies are hoping the latest trial convinces regulators to expand its deployment. European regulators have voiced some support and are letting countries decide if they want to use it....
...Regeneron said its trial met primary and key secondary endpoints: Beyond reducing symptomatic infection risk, the total number of weeks patients experienced symptoms was nearly halved (45%) with REGEN-COV, and the viral burden was cut by 90%-plus, potentially helping halt the disease's spread....
